-

PharmaEssentia to Present at the Annual J.P. Morgan Healthcare Conference on January 16, 2025

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a global commercial biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference Thursday, January 16, 2025 at 1:45 pm. PST.

A live webcast of management's remarks will be available through the News section of PharmaEssentia’s website at https://us.pharmaessentia.com/news/. Replays of the webcast will be archived on the Company's website for at least 30 days.

About PharmaEssentia
PharmaEssentia (TWSE: 6446), headquartered in Taipei, Taiwan, is a commercial-stage, global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversified pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan.

For more information about PharmaEssentia USA, visit our website, LinkedIn or X.

© 2024 PharmaEssentia Corporation. All rights reserved.

Contacts

Investor and Media
Muriel Huang, muriel_huang@pharmaessentia.com

PharmaEssentia Corporation

TSE:6446
Details
Headquarters: Taipei, Taiwan
CEO: Ko-Chung Lin
Employees: 600
Organization: PUB

Release Versions

Contacts

Investor and Media
Muriel Huang, muriel_huang@pharmaessentia.com

More News From PharmaEssentia Corporation

PharmaEssentia to Present Additional BESREMi® Data Across Polycythemia Vera and Essential Thrombocythemia at ASH 2026

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446) today announced it will be presenting one oral presentation, nine posters, and five online publications at the 68th American Society of Hematology (ASH) Annual Meeting, taking place December 12-15 in New Orleans, Louisiana. Following the recent FDA approval of BESREMi® (ropeginterferon alfa-2b-njft) for adults with essential thrombocythemia (ET), its second approved indica...

PharmaEssentia to Participate in Upcoming Jefferies and Citi Healthcare Conferences

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that members of its management team will participate in the following investor conferences: Jefferies London Healthcare Conference Date: November 16-19, 2026 Location: London, United Kingdom Ci...

PharmaEssentia to Present Early-Stage Pipeline Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, Highlighting Immuno-Oncology Approaches for Solid Tumors

BEDFORD, Mass.--(BUSINESS WIRE)--PharmaEssentia Innovation Research Center (PIRC), a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced two poster presentations at the Society for Immunotherapy of Cancer's (SITC) 41st Annual Meeting, taking place November 4-8 in Phoenix, Arizona. The two presentations feature pre...
Back to Newsroom